187 related articles for article (PubMed ID: 21903207)
1. Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1.
Zhao D; Amria S; Hossain A; Sundaram K; Komlosi P; Nagarkatti M; Haque A
Cell Immunol; 2011; 271(2):392-400. PubMed ID: 21903207
[TBL] [Abstract][Full Text] [Related]
2. HLA class II defects in Burkitt lymphoma: bryostatin-1-induced 17 kDa protein restores CD4+ T-cell recognition.
Hossain A; God JM; Radwan FF; Amria S; Zhao D; Bethard JR; Haque A
Clin Dev Immunol; 2011; 2011():780839. PubMed ID: 22162713
[TBL] [Abstract][Full Text] [Related]
3. Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma.
Goldstein OG; Hajiaghamohseni LM; Amria S; Sundaram K; Reddy SV; Haque A
Cancer Immunol Immunother; 2008 Oct; 57(10):1461-70. PubMed ID: 18343923
[TBL] [Abstract][Full Text] [Related]
4. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules.
Chiari R; Hames G; Stroobant V; Texier C; Maillère B; Boon T; Coulie PG
Cancer Res; 2000 Sep; 60(17):4855-63. PubMed ID: 10987298
[TBL] [Abstract][Full Text] [Related]
5. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
6. Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.
Rodríguez T; Méndez R; Del Campo A; Aptsiauri N; Martín J; Orozco G; Pawelec G; Schadendorf D; Ruiz-Cabello F; Garrido F
Immunogenetics; 2007 Feb; 59(2):123-33. PubMed ID: 17180681
[TBL] [Abstract][Full Text] [Related]
7. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
[TBL] [Abstract][Full Text] [Related]
8. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS
Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms regulating enhanced human leukocyte antigen class II-mediated CD4 + T cell recognition of human B-cell lymphoma by resveratrol.
Radwan FF; Zhang L; Hossain A; Doonan BP; God JM; Haque A
Leuk Lymphoma; 2012 Feb; 53(2):305-14. PubMed ID: 21854084
[TBL] [Abstract][Full Text] [Related]
10. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
11. Exosomes from CIITA-transfected CT26 cells enhance anti- tumor effects.
Fan W; Tian XD; Huang E; Zhang JJ
Asian Pac J Cancer Prev; 2013; 14(2):987-91. PubMed ID: 23621273
[TBL] [Abstract][Full Text] [Related]
12. Highly polarized HLA class II antigen processing and presentation by human intestinal epithelial cells.
Hershberg RM; Cho DH; Youakim A; Bradley MB; Lee JS; Framson PE; Nepom GT
J Clin Invest; 1998 Aug; 102(4):792-803. PubMed ID: 9710448
[TBL] [Abstract][Full Text] [Related]
13. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
Muczynski KA; Anderson SK; Pious D
J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
[TBL] [Abstract][Full Text] [Related]
14. Class II transactivator (CIITA) isoform expression and activity in melanoma.
Baton F; Deruyffelaere C; Chapin M; Prod'homme T; Charron D; Al-Daccak R; Alcaide-Loridan C
Melanoma Res; 2004 Dec; 14(6):453-61. PubMed ID: 15577315
[TBL] [Abstract][Full Text] [Related]
15. Accessory cell function of airway epithelial cells.
Oei E; Kalb T; Beuria P; Allez M; Nakazawa A; Azuma M; Timony M; Stuart Z; Chen H; Sperber K
Am J Physiol Lung Cell Mol Physiol; 2004 Aug; 287(2):L318-31. PubMed ID: 15246982
[TBL] [Abstract][Full Text] [Related]
16. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
Novellino L; Renkvist N; Rini F; Mazzocchi A; Rivoltini L; Greco A; Deho P; Squarcina P; Robbins PF; Parmiani G; Castelli C
J Immunol; 2003 Jun; 170(12):6363-70. PubMed ID: 12794170
[TBL] [Abstract][Full Text] [Related]
17. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
[TBL] [Abstract][Full Text] [Related]
18. Human duodenal epithelial cells constitutively express molecular components of antigen presentation but not costimulatory molecules.
Byrne B; Madrigal-Estebas L; McEvoy A; Carton J; Doherty DG; Whelan A; Feighery C; O'Donoghue DP; O'Farrelly C
Hum Immunol; 2002 Nov; 63(11):977-86. PubMed ID: 12392850
[TBL] [Abstract][Full Text] [Related]
19. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
Meissner M; Whiteside TL; Kaufmann R; Seliger B
Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells.
Tsuji T; Matsuzaki J; Caballero OL; Jungbluth AA; Ritter G; Odunsi K; Old LJ; Gnjatic S
J Immunol; 2012 Apr; 188(8):3851-8. PubMed ID: 22427632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
